Met Life Investment Management, LLC Bio Atla, Inc. Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 29, 2024	BUY	$2.83 - $3.87 $70,687 - $96,664	24,978 New	24,978 $74,000
Q2 2023 Aug 10, 2023	BUY	$2.83 - $3.87 $70,687 - $96,664	24,978 New	24,978 $74,000
Q1 2022 May 12, 2022	SELL	$4.38 - $18.78 $21,799 - $93,468	-4,977 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$19.0 - $30.95 $94,563 - $154,038	4,977 New	4,977 $97,000
Q3 2021 Jun 21, 2023	BUY	$29.44 - $43.74 $146,522 - $217,693	4,977 New	4,977 $146,000
Q2 2021 Jun 21, 2023	BUY	$38.07 - $56.17 $189,474 - $279,558	4,977 New	4,977 $210,000
Q1 2021 May 17, 2024	BUY	$32.41 - $70.91 $161,304 - $352,919	4,977 New	4,977 $253,000
Q1 2021 Jun 26, 2023	BUY	$32.41 - $70.91 $161,304 - $352,919	4,977 New	4,977 $253 Million
Q1 2021 Mar 22, 2023	BUY	$32.41 - $70.91 $161,304 - $352,919	4,977 New	4,977 $253,000
Q1 2021 May 14, 2021	BUY	$32.41 - $70.91 $161,304 - $352,919	4,977 New	4,977 $253,000

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $63.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.